March 17, 2016
Allergan: FDA approves Vraylartm
Allergan’s Vraylartm (cariprazine), a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the U.S. As Allergan…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
March 16, 2016
PureTech’s Vedanta Biosciences Appoints New Chief Scientific Officer and Expands to New Facility
PureTech Health plc has announced the appointment of immunology expert and former Genzyme group vice president, Bruce L. Roberts, Ph.D., as Chief Scientific Officer.
March 16, 2016
Georgia Healthcare Group Announces Appointment of Deputy CEO
Georgia Healthcare Group PLC has announced that George Arveladze has been appointed as the Deputy CEO, in charge of the ambulatory and pharmaceutical businesses of the Group, with immediate effect.
March 16, 2016
Sanofi and DiCE Molecules Announce Research Collaboration
Sanofi and DiCE Molecules has announced a five-year global collaboration to discover potential new therapeutics for up to 12 targets that encompass all disease areas of strategic interest to Sanofi.
March 16, 2016
FDA warns public about eye drop bottles with loose safety seals
FDA warns public about eye drop bottles with loose safety seals
March 16, 2016
Drug maker Valeant faces debt default risk; shares plunge 50 percent
Drug maker Valeant faces debt default risk; shares plunge 50 percent
March 15, 2016
Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial
Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial
March 15, 2016
Verona Pharma reports positive results from RPL554 dose-finding study
Verona Pharma reports positive results from RPL554 dose-finding study
March 15, 2016
MedMined Surveillance Advisor named “the best technology for Infection Control and Monitoring”
MedMined Surveillance Advisor named “the best technology for Infection Control and Monitoring”
March 15, 2016
FDA Approves ZEPATIER for the Treatment of Chronic Hepatitis C Infection
On January 28, 2016, the United States Food and Drug Administration (FDA) approved Zepatier (elbasvir and grazoprevir) for the treatment of chronic genotype 1 or 4 hepatitis C virus (HCV) infection in adults.